Drug Profile
Nomacopan - Akari Therapeutics
Alternative Names: Coversin; EV 576; long-acting PAS-nomacopan; PAS-coversin; PAS-nomacopan; rEV 576; rVA576Latest Information Update: 21 Nov 2023
Price :
$50
*
At a glance
- Originator Evolutec
- Developer Akari Therapeutics; Evolutec; US Army Institute of Surgical Research
- Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Antithrombotics; Antivirals; Eye disorder therapies; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Complement C5a inhibitors; Leukotriene B4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Eye disorders
Highest Development Phases
- Phase III Haemolytic uraemic syndrome; Thrombotic microangiopathy
- Phase I/II COVID-19 pneumonia; Keratoconjunctivitis
- Preclinical Asthma; Dry age-related macular degeneration; Haemorrhagic shock; Subarachnoid haemorrhage; Traumatic brain injuries; Uveitis; Wet age-related macular degeneration
- No development reported Guillain-Barre syndrome; Myasthenia gravis; Rheumatoid arthritis; Sjogren's syndrome
- Discontinued Autoimmune disorders; Bullous pemphigoid; Inflammation; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 16 Nov 2023 Akari Therapeutics plans to file an IND application with the US FDA for Dry age-related macular degeneration in 2024
- 29 Sep 2023 Akari Therapeutics plans a Type C meeting with the US FDA for Thrombotic microangiopathy (In adults) in November 2023
- 28 Sep 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-19 pneumonia in Brazil (SC, Injection)